Supernus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	151.37	69.33	75.05	93.12	203.43	288.64
Short-Term Investments	129.79	384.28	179.82	368.21	136.25	133.89
Cash & Short-Term Investments	281.16	453.61	254.87	461.33	339.68	422.53
Cash Growth	-30.27%	77.98%	-44.75%	35.81%	-19.61%	21.74%
Receivables	171.25	142.08	144.16	165.5	148.93	140.88
Inventory	79.4	54.29	77.41	91.54	85.96	48.33
Prepaid Expenses	62.08	36.09	16.68	15.78	27.02	18.68
Total Current Assets	593.89	686.07	493.11	734.15	601.59	630.42
Property, Plant & Equipment	39.39	36.02	42.52	44.08	52.32	58.06
Long-Term Investments	-	-	16.62	93.9	119.17	350.36
Goodwill	119.08	117.02	117.02	117.02	117.52	77.91
Other Intangible Assets	623.48	521.91	599.89	702.46	784.69	364.34
Long-Term Deferred Tax Assets	8.79	-	-	-	-	-
Other Long-Term Assets	35.12	7.05	8.51	10.9	13.87	23.02
Total Assets	1,420	1,368	1,278	1,703	1,689	1,504
Accounts Payable	8.18	4.59	1.96	10.54	9.33	6.15
Accrued Expenses	230.84	180.21	166.26	185.67	199.47	165.62
Current Portion of Long-Term Debt	-	-	-	407.97	7.24	5.32
Current Portion of Leases	10.79	6.89	8.33	6.79	6.48	7.52
Other Current Liabilities	80.83	100.72	113.64	76.99	92.86	60.5
Total Current Liabilities	330.63	292.4	290.2	687.96	315.38	245.11
Long-Term Debt	-	-	-	-	385.23	375.16
Long-Term Leases	31.42	27.38	33.2	36	41.3	48.81
Long-Term Deferred Tax Liabilities	-	4.96	24.96	49.81	85.36	35.22
Other Long-Term Liabilities	8.04	7.6	7.8	42.54	46.04	54.95
Total Liabilities	370.09	332.34	356.16	816.3	873.3	759.24
Common Stock	0.06	0.06	0.06	0.05	0.05	0.05
Additional Paid-In Capital	527.7	479.44	439.49	408.12	434.34	409.33
Retained Earnings	521.98	556.43	482.56	481.25	379.92	326.5
Comprehensive Income & Other	-0.07	-0.19	-0.59	-3.21	1.54	8.98
Shareholders' Equity	1,050	1,036	921.52	886.2	815.85	744.86
Total Liabilities & Equity	1,420	1,368	1,278	1,703	1,689	1,504
Total Debt	42.21	34.27	41.53	450.76	440.25	436.82
Net Cash (Debt)	238.95	419.34	229.96	104.47	18.6	336.08
Net Cash Growth	-34.54%	82.35%	120.12%	461.74%	-94.47%	-37.52%
Net Cash Per Share	4.27	7.49	4.14	1.69	0.34	6.26
Filing Date Shares Outstanding	57.34	55.81	54.73	54.38	53.39	52.92
Total Common Shares Outstanding	57.12	55.74	54.72	54.25	53.26	52.87
Working Capital	263.26	393.67	202.92	46.19	286.21	385.31
Book Value Per Share	18.38	18.58	16.84	16.33	15.32	14.09
Tangible Book Value	307.11	396.8	204.61	66.72	-86.36	302.61
Tangible Book Value Per Share	5.38	7.12	3.74	1.23	-1.62	5.72
Machinery	15.18	14.48	14.03	13.11	14.23	14.64
Construction In Progress	-	-	-	0.21	0.03	-
Leasehold Improvements	14.02	14.02	14.02	14.02	14.37	15.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.